Received Jun 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | 945663 | IM / RA |
Patient reported back to the clinic after 45 minutes of being vaccinated. Facial flushing, itching, localized rash, hives and redness, slight dizziness. Patient A/O x10;NKA; stable, and no breathing difficulties. Cold compress implemented on the face to reduce inflammation and pain; cetirizine 10mg administered, and blood pressure monitored. Patient monitored for 45 minutes, was stable, swelling, itching, hives, and redness reduced, pt. voiced "I feel better, thank you" Patient educated and encourage to monitor flushing and itching and report to urgent care if needed.
DENIED
DENIED
DENIED
NKA
N/A